|
|
Volumn 350, Issue 6262, 2015, Pages 731-
|
|
Baby's leukemia recedes after novel cell therapy
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALEMTUZUMAB;
CD52 ANTIGEN;
TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE;
ANTINEOPLASTIC AGENT;
MONOCLONAL ANTIBODY;
BONE MARROW TRANSPLANTATION;
CANCER IMMUNOTHERAPY;
CANCER INHIBITION;
CELL ISOLATION;
CELL SURVIVAL;
CELL THERAPY;
DISEASE SEVERITY;
DNA MODIFICATION;
FOLLOW UP;
GENETIC ENGINEERING;
HUMAN;
IMMUNE RESPONSE;
INFANT;
LEUKEMIA;
LONG TERM CARE;
LYMPHOCYTE FUNCTION;
NOTE;
PERSONALIZED MEDICINE;
PRIORITY JOURNAL;
T LYMPHOCYTE RECEPTOR GENE;
T LYMPHOCYTE THERAPY;
THERAPY EFFECT;
BIOLOGICAL THERAPY;
FEMALE;
HUMAN GENOME;
IMMUNOLOGY;
IMMUNOTHERAPY;
PROCEDURES;
T LYMPHOCYTE;
TRANSPLANTATION;
TREATMENT OUTCOME;
UNITED KINGDOM;
ANTIBODIES, MONOCLONAL, HUMANIZED;
ANTINEOPLASTIC AGENTS;
CELL- AND TISSUE-BASED THERAPY;
FEMALE;
GENETIC ENGINEERING;
GENOME, HUMAN;
HUMANS;
IMMUNOTHERAPY;
INFANT;
LEUKEMIA;
LONDON;
T-LYMPHOCYTES;
TREATMENT OUTCOME;
|
|
EID: 85047285593
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.350.6262.731 Document Type: Note |
|
Times cited : (9)
|
|
References (0)
|